Molecular and functional profiling of chemotolerant cells unveils nucleoside metabolism-dependent vulnerabilities in medulloblastoma
Open Access
- 17 November 2023
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 11 (1) , 1-16
Abstract
Chemotherapy resistance is considered one of the main causes of tumor relapse, still challenging researchers for the identification of the molecular mechanisms sustaining its emergence. Here, we setup and characterized chemotherapy-resistant models of Medulloblastoma (MB), one of the most lethal pediatric brain tumors, to uncover targetable vulnerabilities associated to their resistant phenotype. Integration of proteomic, transcriptomic and kinomic data revealed a significant deregulation of several pathways in resistant MB cells, converging to cell metabolism, RNA/protein homeostasis, and immune response, eventually impacting on patient outcome. Moreover, resistant MB cell response to a large library of compounds through a high-throughput screening (HTS), highlighted nucleoside metabolism as a relevant vulnerability of chemotolerant cells, with peculiar antimetabolites demonstrating increased efficacy against them and even synergism with conventional chemotherapeutics. Our results suggest that drug-resistant cells significantly rewire multiple cellular processes, allowing their adaptation to a chemotoxic environment, nevertheless exposing alternative actionable susceptibilities for their specific targeting.Keywords
Funding Information
- Fondazione Città della Speranza (IRP18/06)
- Rally Foundation (#20IN28, #21IC16)
- Fondazione Cassa di Risparmio di Padova e Rovigo (20/16 FCR, 17/07_1 FCR)
- Fondazione Just Italia (Più Forti di Tutto)
- Associazione Italiana per la Ricerca sul Cancro (IG #23109, ID 24185)
- Fondazione Umberto Veronesi (#3628, #4420, #4820)
- Università degli Studi di Padova
This publication has 50 references indexed in Scilit:
- Medulloblastomics: the end of the beginningNature Reviews Cancer, 2012
- Molecular subgroups of medulloblastoma: the current consensusActa Neuropathologica, 2011
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Mechanisms of Disease: cancer stem cells—targeting the evil twinNature Clinical Practice Oncology, 2008
- Resistance mechanisms to cancer chemotherapyFrontiers in Bioscience-Landmark, 2008
- Mutation as a Stress Response and the Regulation of EvolvabilityCritical Reviews in Biochemistry and Molecular Biology, 2007
- Novel patterns of genome rearrangement and their association with survival in breast cancerGenome Research, 2006
- Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJournal of Clinical Oncology, 2006
- Neurocognitive Consequences of Risk-Adapted Therapy for Childhood MedulloblastomaJournal of Clinical Oncology, 2005
- Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemiaBlood, 2004